Meghan Ann Baker, M.D., Sc.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cross Infection | 9 | 2022 | 1416 | 1.970 |
Why?
|
| Pneumococcal Vaccines | 2 | 2020 | 391 | 1.070 |
Why?
|
| Bacteremia | 2 | 2022 | 962 | 1.050 |
Why?
|
| Infection Control | 9 | 2022 | 966 | 0.980 |
Why?
|
| Ralstonia pickettii | 1 | 2022 | 4 | 0.890 |
Why?
|
| Water Purification | 1 | 2023 | 48 | 0.880 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 4 | 2021 | 253 | 0.830 |
Why?
|
| Vaccines | 3 | 2015 | 822 | 0.820 |
Why?
|
| Disease Outbreaks | 5 | 2022 | 1772 | 0.780 |
Why?
|
| Sentinel Surveillance | 5 | 2020 | 281 | 0.780 |
Why?
|
| Product Surveillance, Postmarketing | 3 | 2015 | 430 | 0.760 |
Why?
|
| Catheter-Related Infections | 1 | 2022 | 252 | 0.680 |
Why?
|
| Seizures, Febrile | 1 | 2020 | 111 | 0.650 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2022 | 274 | 0.650 |
Why?
|
| Pseudomonas Infections | 1 | 2022 | 613 | 0.630 |
Why?
|
| United States Food and Drug Administration | 4 | 2021 | 1584 | 0.620 |
Why?
|
| Delayed Diagnosis | 2 | 2021 | 441 | 0.600 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2017 | 104 | 0.580 |
Why?
|
| Hospitals | 8 | 2023 | 3952 | 0.570 |
Why?
|
| Drug Utilization Review | 1 | 2017 | 245 | 0.560 |
Why?
|
| Urinary Tract Infections | 1 | 2022 | 788 | 0.540 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2019 | 469 | 0.540 |
Why?
|
| Tuberculosis | 4 | 2012 | 1912 | 0.540 |
Why?
|
| Health Personnel | 6 | 2022 | 3218 | 0.530 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 687 | 0.520 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2022 | 1354 | 0.500 |
Why?
|
| Influenza Vaccines | 2 | 2020 | 738 | 0.500 |
Why?
|
| Vaccination | 2 | 2019 | 3278 | 0.490 |
Why?
|
| Masks | 5 | 2023 | 197 | 0.490 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2019 | 546 | 0.480 |
Why?
|
| Blood Transfusion | 1 | 2021 | 1301 | 0.480 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2017 | 536 | 0.440 |
Why?
|
| Respiratory Insufficiency | 1 | 2021 | 1199 | 0.420 |
Why?
|
| Pneumonia, Viral | 5 | 2021 | 3240 | 0.410 |
Why?
|
| Virus Diseases | 3 | 2023 | 711 | 0.410 |
Why?
|
| Occupational Diseases | 1 | 2020 | 1471 | 0.410 |
Why?
|
| Risk Management | 1 | 2015 | 571 | 0.400 |
Why?
|
| Immunization | 2 | 2015 | 1256 | 0.400 |
Why?
|
| Respiratory Tract Infections | 3 | 2023 | 961 | 0.390 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 3133 | 0.360 |
Why?
|
| Cation Transport Proteins | 1 | 2012 | 327 | 0.340 |
Why?
|
| Diabetes Complications | 3 | 2012 | 1359 | 0.310 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2023 | 3537 | 0.310 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2015 | 1164 | 0.270 |
Why?
|
| Antitubercular Agents | 3 | 2019 | 1320 | 0.260 |
Why?
|
| Data Collection | 1 | 2013 | 3341 | 0.240 |
Why?
|
| Burkholderia cepacia | 1 | 2022 | 22 | 0.220 |
Why?
|
| Burkholderia cepacia complex | 1 | 2022 | 25 | 0.220 |
Why?
|
| Burkholderia Infections | 1 | 2022 | 44 | 0.210 |
Why?
|
| International Classification of Diseases | 2 | 2021 | 867 | 0.210 |
Why?
|
| Pandemics | 6 | 2022 | 8388 | 0.210 |
Why?
|
| Ice | 1 | 2023 | 104 | 0.210 |
Why?
|
| Humans | 49 | 2023 | 744343 | 0.200 |
Why?
|
| Inpatients | 3 | 2023 | 2518 | 0.200 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2023 | 139 | 0.200 |
Why?
|
| United States | 12 | 2023 | 69872 | 0.200 |
Why?
|
| Delivery of Health Care | 5 | 2022 | 5319 | 0.200 |
Why?
|
| Hematemesis | 1 | 2021 | 23 | 0.200 |
Why?
|
| Insurance Claim Review | 2 | 2017 | 720 | 0.190 |
Why?
|
| Leptospirosis | 1 | 2021 | 29 | 0.190 |
Why?
|
| Influenza, Human | 3 | 2023 | 1479 | 0.190 |
Why?
|
| Infant | 7 | 2021 | 35136 | 0.190 |
Why?
|
| Air Microbiology | 1 | 2020 | 87 | 0.180 |
Why?
|
| Hemoptysis | 1 | 2021 | 155 | 0.180 |
Why?
|
| Water | 2 | 2022 | 1395 | 0.170 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2023 | 329 | 0.170 |
Why?
|
| Asthma | 1 | 2017 | 6011 | 0.160 |
Why?
|
| Vaccines, Conjugate | 1 | 2020 | 333 | 0.160 |
Why?
|
| Immunization Schedule | 1 | 2019 | 221 | 0.160 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 738 | 0.160 |
Why?
|
| Inhalation Exposure | 1 | 2020 | 443 | 0.150 |
Why?
|
| Diabetes Mellitus | 3 | 2012 | 5751 | 0.150 |
Why?
|
| Risk Adjustment | 1 | 2021 | 594 | 0.140 |
Why?
|
| Latent Tuberculosis | 1 | 2019 | 225 | 0.140 |
Why?
|
| Cluster Analysis | 2 | 2020 | 2715 | 0.130 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2022 | 1219 | 0.130 |
Why?
|
| Aerosols | 3 | 2022 | 625 | 0.120 |
Why?
|
| Administration, Inhalation | 1 | 2017 | 1105 | 0.120 |
Why?
|
| Ohio | 1 | 2015 | 337 | 0.120 |
Why?
|
| Communicable Diseases | 1 | 2021 | 880 | 0.110 |
Why?
|
| Hospitalization | 3 | 2021 | 10262 | 0.110 |
Why?
|
| Escherichia coli Infections | 1 | 2016 | 532 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 15519 | 0.110 |
Why?
|
| Child, Preschool | 4 | 2021 | 41006 | 0.100 |
Why?
|
| Drug Combinations | 1 | 2017 | 1959 | 0.100 |
Why?
|
| Papillomaviridae | 1 | 2018 | 1119 | 0.100 |
Why?
|
| Papillomavirus Vaccines | 1 | 2018 | 491 | 0.100 |
Why?
|
| Female | 18 | 2023 | 380194 | 0.100 |
Why?
|
| Male | 16 | 2021 | 350118 | 0.100 |
Why?
|
| Taiwan | 1 | 2012 | 496 | 0.090 |
Why?
|
| Adult | 14 | 2021 | 214055 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 17446 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2021 | 8324 | 0.090 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 2569 | 0.090 |
Why?
|
| Adolescent | 8 | 2021 | 85781 | 0.090 |
Why?
|
| Aged | 8 | 2021 | 163280 | 0.090 |
Why?
|
| Child | 7 | 2021 | 77709 | 0.080 |
Why?
|
| Papillomavirus Infections | 2 | 2018 | 1587 | 0.080 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2016 | 1035 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 57776 | 0.080 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2019 | 1832 | 0.080 |
Why?
|
| Anaphylaxis | 1 | 2015 | 746 | 0.080 |
Why?
|
| Middle Aged | 10 | 2021 | 213383 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2017 | 2107 | 0.080 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 1637 | 0.080 |
Why?
|
| Opportunistic Infections | 1 | 2010 | 389 | 0.070 |
Why?
|
| Health Services Research | 1 | 2015 | 1836 | 0.070 |
Why?
|
| Massachusetts | 1 | 2020 | 8663 | 0.070 |
Why?
|
| Infant, Newborn | 2 | 2019 | 25625 | 0.070 |
Why?
|
| Young Adult | 7 | 2019 | 56430 | 0.070 |
Why?
|
| South Africa | 1 | 2012 | 1731 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 15076 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2019 | 23338 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2021 | 7729 | 0.070 |
Why?
|
| Incidence | 4 | 2023 | 20947 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2011 | 2618 | 0.060 |
Why?
|
| Travel | 2 | 2021 | 788 | 0.060 |
Why?
|
| Malaria | 2 | 2008 | 1239 | 0.060 |
Why?
|
| Quality of Health Care | 1 | 2020 | 4371 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2016 | 3589 | 0.060 |
Why?
|
| Escherichia coli | 1 | 2016 | 4217 | 0.060 |
Why?
|
| Electronic Health Records | 1 | 2021 | 4468 | 0.060 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2022 | 1877 | 0.060 |
Why?
|
| Antibodies, Bacterial | 2 | 2021 | 1470 | 0.060 |
Why?
|
| Venous Thromboembolism | 1 | 2015 | 1671 | 0.060 |
Why?
|
| Disease Notification | 1 | 2003 | 97 | 0.060 |
Why?
|
| Seizures | 1 | 2015 | 2859 | 0.050 |
Why?
|
| Enterobacter | 1 | 2022 | 46 | 0.050 |
Why?
|
| Risk Factors | 5 | 2021 | 72290 | 0.050 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 2703 | 0.050 |
Why?
|
| Lung | 1 | 2021 | 9856 | 0.050 |
Why?
|
| Age Factors | 1 | 2019 | 18370 | 0.050 |
Why?
|
| Neoplasms | 2 | 2021 | 21683 | 0.050 |
Why?
|
| Drug Contamination | 1 | 2022 | 147 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 5442 | 0.050 |
Why?
|
| Ventilation | 1 | 2021 | 127 | 0.050 |
Why?
|
| Syphilis | 1 | 2003 | 227 | 0.050 |
Why?
|
| beta-Lactamases | 1 | 2022 | 306 | 0.050 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 35 | 0.050 |
Why?
|
| Time Factors | 2 | 2019 | 40075 | 0.050 |
Why?
|
| Plasmapheresis | 1 | 2021 | 211 | 0.050 |
Why?
|
| Personnel, Hospital | 1 | 2021 | 283 | 0.040 |
Why?
|
| Anemia, Megaloblastic | 1 | 1999 | 25 | 0.040 |
Why?
|
| Mexico | 1 | 2021 | 690 | 0.040 |
Why?
|
| Tuberculin Test | 1 | 2019 | 214 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2011 | 10252 | 0.040 |
Why?
|
| Vaccines, Attenuated | 2 | 2015 | 342 | 0.040 |
Why?
|
| Thiamine | 1 | 1999 | 152 | 0.040 |
Why?
|
| Protozoan Vaccines | 1 | 1997 | 13 | 0.040 |
Why?
|
| Respiratory System | 1 | 2021 | 557 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 7785 | 0.040 |
Why?
|
| Entamoeba histolytica | 1 | 1997 | 30 | 0.040 |
Why?
|
| Communication Barriers | 1 | 2021 | 398 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 7181 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2017 | 40561 | 0.040 |
Why?
|
| Plasmids | 1 | 2022 | 2307 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 12354 | 0.040 |
Why?
|
| Staphylococcus epidermidis | 1 | 1996 | 117 | 0.030 |
Why?
|
| Cross-Sectional Studies | 3 | 2016 | 25043 | 0.030 |
Why?
|
| Antibodies, Protozoan | 1 | 1997 | 253 | 0.030 |
Why?
|
| Particle Size | 1 | 2020 | 1642 | 0.030 |
Why?
|
| Bacterial Typing Techniques | 1 | 1996 | 256 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2003 | 2453 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 2021 | 862 | 0.030 |
Why?
|
| Vaccines, Inactivated | 1 | 2015 | 184 | 0.030 |
Why?
|
| Cholera Toxin | 1 | 1997 | 556 | 0.030 |
Why?
|
| Deafness | 1 | 1999 | 458 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2020 | 77449 | 0.030 |
Why?
|
| Vaccines, Synthetic | 1 | 1997 | 634 | 0.030 |
Why?
|
| Emigrants and Immigrants | 1 | 2021 | 522 | 0.030 |
Why?
|
| Antimalarials | 1 | 2001 | 905 | 0.030 |
Why?
|
| Geography | 1 | 2016 | 669 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2012 | 12720 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 15540 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2021 | 1130 | 0.030 |
Why?
|
| Fever | 1 | 2021 | 1616 | 0.030 |
Why?
|
| Protozoan Proteins | 1 | 1997 | 827 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2015 | 53288 | 0.020 |
Why?
|
| Vibrio cholerae | 1 | 1997 | 806 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2001 | 2684 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2020 | 2708 | 0.020 |
Why?
|
| Health Policy | 1 | 2021 | 2661 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2022 | 3848 | 0.020 |
Why?
|
| Fibroblasts | 1 | 1999 | 4161 | 0.020 |
Why?
|
| Boston | 1 | 2021 | 9313 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2021 | 3679 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 1996 | 6171 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 2008 | 240 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 7279 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 1996 | 4328 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2011 | 63114 | 0.020 |
Why?
|
| Reagins | 1 | 2003 | 7 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2021 | 21746 | 0.010 |
Why?
|
| Chicago | 1 | 2003 | 240 | 0.010 |
Why?
|
| Apoptosis | 1 | 1999 | 9727 | 0.010 |
Why?
|
| Mass Screening | 2 | 2010 | 5255 | 0.010 |
Why?
|
| Kenya | 1 | 2001 | 685 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 7659 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 20129 | 0.010 |
Why?
|
| North America | 1 | 2001 | 1249 | 0.010 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 1996 | 143 | 0.010 |
Why?
|
| Algorithms | 1 | 2016 | 13881 | 0.010 |
Why?
|
| Europe | 1 | 2001 | 3339 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 1681 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2001 | 4933 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 14722 | 0.010 |
Why?
|
| Syndrome | 1 | 1999 | 3251 | 0.010 |
Why?
|
| Species Specificity | 1 | 1996 | 2478 | 0.010 |
Why?
|
| DNA Primers | 1 | 1996 | 2892 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 1996 | 1465 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1997 | 3913 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1997 | 3772 | 0.010 |
Why?
|
| Intestines | 1 | 1997 | 1924 | 0.000 |
Why?
|
| Carrier Proteins | 1 | 1999 | 5021 | 0.000 |
Why?
|
| Base Sequence | 1 | 1996 | 12797 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 18111 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1999 | 19229 | 0.000 |
Why?
|
| Reproducibility of Results | 1 | 1996 | 19905 | 0.000 |
Why?
|
| Mutation | 1 | 1999 | 29786 | 0.000 |
Why?
|
| Mice | 1 | 1997 | 81183 | 0.000 |
Why?
|
| Animals | 1 | 1997 | 168757 | 0.000 |
Why?
|